Basic Information
Vimizim
Regulatory Information
EMEA/H/C/002779
Authorised
April 27, 2014
13
November 19, 2023
Company Information
Ireland
Shanbally Ringaskiddy County Cork P43 R298
Biomarin International Limited
Drug Classification
Orphan MedicineAdditional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Vimizim. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Vimizim. For practical information about using Vimizim, patients should read the package leaflet or contact their doctor or pharmacist.